Egyptian Rheumatologist最新文献

{"title":"Disease- and mental health-related predictors of quality of life among radiographic axial spondyloarthritis patients","authors":"Suzan S. Al-Adle ,&nbsp;Radwa S. ELbahnasy ,&nbsp;Shirin M. El-Makawi ,&nbsp;Hania S. Zayed","doi":"10.1016/j.ejr.2025.09.003","DOIUrl":"10.1016/j.ejr.2025.09.003","url":null,"abstract":"<div><h3>Background</h3><div>Radiographic axial spondyloarthritis (r-axSpA) significantly impacts health-related quality of life (HRQoL).</div></div><div><h3>Aim of the work</h3><div>To evaluate the disease-and mental health-related predictors of HRQoL in r-axSpA patients.</div></div><div><h3>Patients and methods</h3><div>Fifty-five r-axSpA patients and 55 age-, sex- and education-matched healthy controls were studied. Patients were evaluated by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI) and patient global (PG) assessment of disease activity. Patients and controls were evaluated by the Short Form-36 (SF-36), its physical and mental component summaries (PCS and MCS, respectively), the Depression, Anxiety and Stress scale (DASS) and the Montreal Cognitive Assessment (MoCA)-Basic test.</div></div><div><h3>Results</h3><div>Patients’ mean age was 36.4 ± 7.48 years, median disease duration 10 years with interquartile range (IQR) (6–14) and 47 (85.5 %) were males. DASS scores were significantly higher while MoCA, PCS and MCS scores were lower in patients than controls, p &lt; 0.001. BASDAI (r = −0.701), BASFI (r = −0.73), BASMI (r = −0.52), PG (r = −0.51), depression (r = −0.73), anxiety (r = −0.627) and stress (r = −0.691) scores showed significant negative correlations with PCS, p &lt; 0.001. BASDAI (r = −0.602), BASFI (r = −0.668), BASMI (r = −0.37), PG (r = −0.45), depression (r = −0.74), anxiety (r = −0.63) and stress (r = −0.68) showed significant negative correlations with MCS; p &lt; 0.001. MoCA significantly correlated with PCS (r = 0.36, p = 0.007) and MCS (r = 0.36, p = 0.008). On multivariable logistic regression analyses, PG and stress were independent predictors for PCS (β = −0.22, p = 0.041 and β = −0.35, p = 0.038, respectively), and stress was an independent predictor for MCS (β = −0.39, p = 0.035).</div></div><div><h3>Conclusion</h3><div>The PG assessment and stress scale are predictors of HRQoL in r-axSpA patients.</div></div>","PeriodicalId":46152,"journal":{"name":"Egyptian Rheumatologist","volume":"47 4","pages":"Pages 232-237"},"PeriodicalIF":1.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145117678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Calprotectin in patients with axial spondyloarthritis: Clinical features, disease activity and imaging","authors":"Noha H. Shedid,&nbsp;Noran O. El-Azizi,&nbsp;Maha A. El-Serwy,&nbsp;Zainab A. Khodary,&nbsp;Safaa A. Hussein","doi":"10.1016/j.ejr.2025.06.001","DOIUrl":"10.1016/j.ejr.2025.06.001","url":null,"abstract":"<div><h3>Aim of the work</h3><div>The aim of the current study was to examine both serum and fecal calprotectin (sCal and fCal) levels in patients with axial spondyloarthritis (axSpA) and to evaluate their potential relations to clinical features, disease activity and imaging.</div></div><div><h3>Patients and methods</h3><div>This study included 40 axSpA patients and 18 controls. Disease activity using AS disease activity score (ASDAS), sacroiliac joints radiography and magnetic resonance imaging (MRI) were assessed. sCal and fCal were measured.</div></div><div><h3>Results</h3><div>The axSpA patients were 57.5 % males, with a mean age of 39.8±11.5 years and a median disease duration (IQR) of 4.5 (1.7–11.5) years. The median sCal and fCal levels were significantly higher in axSpA patients compared to controls (p&lt; 0.001). There were no differences in median sCal and fCal levels in axSpA patients concerning demographic data, HLA-B27, extra-articular manifestations, intestinal symptoms and biologics treatment (p&gt; 0.05). A significant increase in median sCal and fCal levels along with the increase in clinical disease activity grade was found (p&lt; 0.0001 and p= 0.003, respectively). Both sCal and fCal were significantly correlating with each other (p= 0.003), with ASDAS score (p= 0.003 and p= 0.01, respectively) and negatively with hemoglobin (p= 0.01 and p= 0.009, respectively). An increase in median sCal levels was observed along with the increase in grade severity of sacroiliitis on MRI (p= 0.06).</div></div><div><h3>Conclusion</h3><div>Serum and fecal calprotectin levels were significantly increased in axSpA patients and associated with disease activity. Both were having good specificity and sensitivity as potential diagnostic biomarkers for the disease.</div></div>","PeriodicalId":46152,"journal":{"name":"Egyptian Rheumatologist","volume":"47 4","pages":"Pages 161-167"},"PeriodicalIF":1.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144470333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frequency and clinical impact of fibromyalgia among patients with multiple sclerosis in Saudi Arabia: A cross-sectional study","authors":"Hind Abdullah Alnajashi","doi":"10.1016/j.ejr.2025.08.001","DOIUrl":"10.1016/j.ejr.2025.08.001","url":null,"abstract":"<div><h3>Background</h3><div>Pain is a prevalent and disabling symptom in multiple sclerosis (MS). Fibromyalgia (FM), a chronic widespread pain syndrome, may coexist with MS and exacerbate fatigue, anxiety, depression, and poor quality of life (QoL). While this association has been studied in Western populations, data from Saudi-Arabia and the Middle-East are limited.</div></div><div><h3>Aim of the work</h3><div>To determine the frequency of FM in Saudi MS patients and assess its impact on fatigue, disability, depression, anxiety, and quality of life as well as its association with disease characteristics and treatment.</div></div><div><h3>Patients and methods</h3><div>This retrospective study included 73 Saudi adults with MS. FM was screened using the Arabic Fibromyalgia Rapid Screening Tool (FiRST). Fatigue was assessed using the modified fatigue impact scale (MFIS), disability via expanded disability status scale (EDSS), depression with the patient health questionnaire (PHQ-9), anxiety with the generalized anxiety disorder (GAD-7) and QoL with the MS international QoL (MusiQoL) questionnaire.</div></div><div><h3>Results</h3><div>The mean patient age was 37.3 ± 10.2 years; 52 females and 21 males. FM was detected in 11 (15.1 %) patients. Disease-modifying therapies were significantly less frequently received by patients with FM (p = 0.015). FIRST score significantly correlated with MFIS (r = 0.45,p &lt; 0.0001), PHQ-9 (r = 0.3,p = 0.009) and GAD-7 (r = 0.29,p = 0.013) and inversely with MusiQoL (r = -0.3,p = 0.011). In regression analysis, fatigue remained the only significant predictor of FM.</div></div><div><h3>Conclusion</h3><div>FM is not uncommon in Saudi MS patients and is associated with fatigue, depression, anxiety, and reduced QoL. Fatigue emerged as a significant predictor of FM. Early identification and integrated management of FM may improve outcomes in MS.</div></div>","PeriodicalId":46152,"journal":{"name":"Egyptian Rheumatologist","volume":"47 4","pages":"Pages 212-215"},"PeriodicalIF":1.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144860287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asymptomatic hyperuricemia and the risk of colistin-induced acute kidney injury in critically-ill patients with ventilator-associated pneumonia","authors":"Alia H. Abd El Fatah,&nbsp;Mohamed M.Y. Khaled,&nbsp;Mohammed S. Sayed,&nbsp;Mohamed A. Fakher,&nbsp;Sherif R.A. Mohamed","doi":"10.1016/j.ejr.2025.07.001","DOIUrl":"10.1016/j.ejr.2025.07.001","url":null,"abstract":"<div><h3>Background</h3><div>Hyperuricemia has been associated with many chronic metabolic diseases, such as cardiovascular disease, chronic kidney disease, and metabolic syndrome.</div></div><div><h3>Aim of the work</h3><div>To reveal the risk of hyperuricemia and its association with development of acute kidney injury (AKI) during treatment with colistin incritically-illpatients with multidrug and extensive drug resistant ventilator-associated pneumonia not known to be hyperuricemic.</div></div><div><h3>Patients and methods</h3><div>This study included 60 patients with ventilator-associated pneumonia admitted to the intensive care unit (ICU): 23 with hyperuricemia and 37with normal serum uric acid (SUA) levels. The APACHE II (Acute Physiology And Chronic Health Evaluation) and Sequential Organ Failure Assessment (SOFA) were scored. All patients were receiving intravenous colistin 2.5–5 mg/kg/d in 2–4 divided doses.</div></div><div><h3>Results</h3><div>The mean age of the patients was 61.3 ± 14.4 years, 17 females (F:M 1:2.19), the APACHE II and SOFA were lower in those with hyperuricemia (20.5 ± 6.3 and 16.0 ± 4.9) compared to those with normal SUA (24.8 ± 9.3 and 8.7 ± 5.6; p = 0.0.04 and p = 0.001). 12 (52.1 %) patients with hyperuricemia developed AKI and 11 (47.8 %) died while 5 (13.5 %) developed AKI and 17 (45.9 %) died in those with normal SUA (p = 0.001 and p = 0.89 respectively). The area under the curve (AUC) for SUA levels predicting AKI was 0.77 (95 %CI:0.62–0.9) at &gt; 7 mg/dL (sensitivity 71 %, specificity 77 %) (p = 0.001).</div></div><div><h3>Conclusion</h3><div>Asymptomatic hyperuricemia is a potential risk factor for AKI in critically-ill patients with multidrug resistant ventilator-associated pneumonia. It may play a role in the development of sepsis-related AKI, and managing hyperuricemia could potentially serve as an effective strategy to prevent its development.</div></div>","PeriodicalId":46152,"journal":{"name":"Egyptian Rheumatologist","volume":"47 4","pages":"Pages 197-200"},"PeriodicalIF":1.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144679822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolving role of long non-coding (lnc) RNA RP11-273G15.2, mRNA-RSAD2 and mRNA-IFI44 in systemic lupus erythematosus patients","authors":"Basma R. Sakr ,&nbsp;Neama M Abdelazim ,&nbsp;Olfat G. Shaker ,&nbsp;Mona G. Nada ,&nbsp;Marwa Mamdouh","doi":"10.1016/j.ejr.2025.07.002","DOIUrl":"10.1016/j.ejr.2025.07.002","url":null,"abstract":"<div><div><strong><em>Aim of the work:</em></strong> To assess expression level of long non-coding (lnc) RNA RP11-273G15.2, microRNA (mRNA) RSAD2, and mRNAIFI44 in systemic lupus erythematosus (SLE) patients and to study their relationship with clinical manifestations, hematological indices, and disease activity. <strong><em>Patients and methods</em>:</strong> This study recruited 40 SLE patients and 40 controls. SLE disease activity index (SLEDAI) was assessed. Quantitative analysis by real-time polymerized-chain reaction was accomplished for lncRNA RP11-273G15.2, mRNA-RSAD2 and mRNA-IFI44. <strong><em>Results:</em></strong> The mean age of the patients was 33.4 ± 8.1 years, 36 females (F:M 9:1) and disease duration 7.4 ± 6.2 years. The mRNA IFI44 was significantly upregulated in patients (p = 0.004), while lnc RNA RP11-273G15.2 and mRNA-RSAD2 were comparable between patients and controls. The lnc RNA RP11-273G15.2, mRNA IFI44 and mRNA RSAD2 were similar between patients with and without musculoskeletal, cardiac, pulmonary, mucocutaneous, central nervous system, or renal manifestations. The mRNA RSAD2 exhibited significantly lower expression level in patients with history of thrombosis (p = 0.03). The lnc RNA RP11-273G15.2, mRNA-IFI44 and mRNA-RSAD2 were comparable in relation to the other blood indices anti-dsDNA positivity and complement consumption. There was no association of any of the studied parameters with SLEDAI. <strong><em>Conclusion:</em></strong> The mRNA IFI44 was significantly upregulated in SLE patients signifying its role in the molecular pathophysiology of SLE, while lncRNA RP11-273G15.2, and mRNA-RSAD2 were comparable between patients and controls. The lncRNA RP11-273G15.2, mRNA-IFI44 and mRNA-RSAD2 were not related to clinical manifestations, hematological indices, immune profile, or disease activity of SLE patients, apart from significant down regulation of mRNA-RSAD2 in patients with history of thrombosis.</div></div>","PeriodicalId":46152,"journal":{"name":"Egyptian Rheumatologist","volume":"47 4","pages":"Pages 192-196"},"PeriodicalIF":1.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144665576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of dose-dependent methotrexate therapy on renal functions in patients with rheumatoid arthritis","authors":"Dalia M. Gamal ,&nbsp;Ghada Maged ,&nbsp;Marwa Abdo ,&nbsp;Reem M. Elsharabasy ,&nbsp;Sara F. Samaan","doi":"10.1016/j.ejr.2025.06.004","DOIUrl":"10.1016/j.ejr.2025.06.004","url":null,"abstract":"<div><h3>Aim of the work</h3><div>To study the dose-dependent effects of methotrexate (MTX) on renal functions and estimated glomerular filtration rate (eGFR<strong>)</strong> after 1 and 3 years of MTX therapy in rheumatoid arthritis (RA) patients.</div></div><div><h3>Patients and methods</h3><div>Medical records of 360 RA patients were reviewed. Disease activity score (DAS28) was recorded. Doses of MTX, concomitant therapies, and estimated glomerular filtration rate (eGFR) were reviewed at baseline, after 1 and 3 years of therapy.</div></div><div><h3>Results</h3><div>The mean age of patients was 44.6 ± 13.7 years, 80.6 % were females and disease duration was 9.9 ± 6.5 years. 36.4 % had moderate disease activity, 26.1 % high, 21.4 % low and 16.1 % in remission. There was a significant decline in eGFR after 1and 3 years of MTX therapy (p &lt; 0.001) where at baseline it was 100.2 ± 22.6, after 1 year 91.5 ± 23.7 and after 3 years 82 ± 18.7. eGFR was similar in patients receiving MTX doses &lt; 10 mg, 10–15 and &gt; 15 mg/week (after 1 year p = 0.1, after 3 years p = 0.36). On regression, after 3 years, age and MTX therapy were significantly associated with decline in eGFR (p = 0.001 and p = 0.034) respectively. Seventeen patients (4.7 %) developed renal impairment (eGFR &lt; 60 ml/min) after 1 year of MTX versus 9 (3.4 %) after 3 years. At cut off dose 18 mg/week, sensitivity 70.6 % and specificity 53.4 %, MTX could predict renal impairment after 1 year (p = 0.102) and at 15 mg/week after 3 years, sensitivity 82.4 % and specificity 36.1 % (p = 0.068).</div></div><div><h3>Conclusion</h3><div>Low dose MTX has a potential nephrotoxic effect, mandating close monitoring of renal functions for patients on MTX therapy.</div></div>","PeriodicalId":46152,"journal":{"name":"Egyptian Rheumatologist","volume":"47 4","pages":"Pages 182-186"},"PeriodicalIF":1.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144522527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular involvement in Behçet’s disease patients: Carotid atherosclerosis, neutrophil–lymphocyte ratio, platelet-lymphocyte ratio, and serum asymmetric dimethylarginine","authors":"Omima A. Sayed ,&nbsp;Rasha A. Abdel-Magied ,&nbsp;Hazem M.A. Farrag ,&nbsp;Mostafa A. Abu Elela ,&nbsp;Abdallah M.M. Safwat ,&nbsp;Ahmed M. Abdel-Nasser","doi":"10.1016/j.ejr.2025.07.004","DOIUrl":"10.1016/j.ejr.2025.07.004","url":null,"abstract":"<div><h3>Aim of the work</h3><div>To assess the frequency of subclinical atherosclerosis in Behçet’s disease (BD) and the influence of neutrophil–lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and serum asymmetric dimethylarginine (ADMA) compared to traditional cardiovascular risk factors and their relation to the disease characteristics.</div></div><div><h3>Patients and methods</h3><div>This study included 60 BD patients and 30 age and sex matched healthy controls. The BD current activity form (BDCAF) was scored. Traditional cardiovascular risk factors were evaluated. Complete blood count was assessed and both NLR and PLR were calculated. Serum ADMA level was measured. Radiological evaluation of carotid intima media thickness (CIMT) was performed.</div></div><div><h3>Results</h3><div>The mean age of patients was 36.5 ± 10 years and were 48 males and 12 females (M:F 4:1). BD patients had significantly higher CIMT and carotid atherosclerotic plaques compared to the control (0.53 ± 0.14 versus 0.41 ± 0.09, p &lt; 0.001 and 21.7 % versus 0 % respectively) despite similar rate of traditional cardiovascular risk factors. CIMT of BD patients correlated with age (r = 0.38,p = 0.003), disease duration (r = 0.3,p = 0.02), presence of ocular manifestation (r = 0.31,p = 0.02), waist/hip ratio (WHR)(r = 0.29,p = 0.03), NLR (r = 0.42, p = 0.001), PLR (r = 0.27, p = 0.04) and ADMA (r = 0.5,p &lt; 0.001). Only serum ADMA level was found to be a significant determinant of CIMT in BD (p &lt; 0.001), contributing in 37.9 % of the variance of CIMT. NLR, PLR and ADMA can differentiate BD with subclinical atherosclerosis at cut-off values 2.36, 125.51 and 1.27 umol/L respectively.</div></div><div><h3>Conclusion</h3><div>BD is associated with an increased rate of subclinical atherosclerosis, which is best determined by increased hematological indices and serum ADMA level rather than traditional cardiovascular risk factors.</div></div>","PeriodicalId":46152,"journal":{"name":"Egyptian Rheumatologist","volume":"47 4","pages":"Pages 201-206"},"PeriodicalIF":1.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144704362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of clinical characteristics of patients with Behҫet’s disease in two different geographical areas in the United States","authors":"Hamdy Ahmed ,&nbsp;Sebastian E. Sattui ,&nbsp;Dongmei Sun ,&nbsp;Ammar Alkassm ,&nbsp;Angelo Gaffo","doi":"10.1016/j.ejr.2025.06.002","DOIUrl":"10.1016/j.ejr.2025.06.002","url":null,"abstract":"<div><h3>Aim of the work</h3><div>The current data regarding regional differences in the characteristics of Behҫet disease (BD) within the United States are scarce. The aim of the study is to explore these differences in two distinct regions of the United States: Northeast and Southeast.</div></div><div><h3>Patients and Methods</h3><div>This chart review study was conducted at three medical centers. Medical records from patients with ICD-9/10 (136.1/M25.2) codes for BD between 2012 and 2019 were reviewed. Cases included fulfilled the international criteria for BD (ICBD) and International Study Group (ISG) criteria. Data on demographics, clinical and laboratory features was collected. Characteristics were compared by geographic region, sex, and race/ethnicity.</div></div><div><h3>Results</h3><div>A total of 153 patients met ICBD criteria; 77 Northeast and 76 Southeast. The majority of the patients were female (73 %), and white race (73 %), with and median age at diagnosis of 31 years. There was a greater proportion of White non-Hispanic patients in southeast US (85.3 % vs 61 %) and more Hispanic in Northeast (11 % vs 0 %). Females had a higher incidence of genital ulcers (92.5 % vs 69 %, p = 0.01) and arthralgia (34.2 % vs 14.3 %, p = 0.03). Similar trends of race/ethnicity were found using ISG criteria, but no differences in clinical characteristics. Males were more frequent in patients with positive HLA-B51 (50 %) vs negative (22.6 %) (p = 0.048), associated with fewer genital ulcers (55.6 % vs 87 %, p = 0.013), and more gastrointestinal involvement (50 % vs 16.1 %, p = 0.01).</div></div><div><h3>Conclusion</h3><div>In the US, few differences in demographic and clinical features were observed among patients with BD in two different geographical regions.</div></div>","PeriodicalId":46152,"journal":{"name":"Egyptian Rheumatologist","volume":"47 4","pages":"Pages 187-191"},"PeriodicalIF":1.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144535573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Class V membranous nephropathy in patients with systemic lupus erythematosus: Clinical characteristics, outcome and prognosis","authors":"Nermeen Samy,&nbsp;Sherin H. Hamza,&nbsp;Fatma I. Mabrouk,&nbsp;Duaa F. Atyaallah,&nbsp;Mohammed M. Mohammed","doi":"10.1016/j.ejr.2025.07.003","DOIUrl":"10.1016/j.ejr.2025.07.003","url":null,"abstract":"<div><h3>Aim of the work</h3><div>To study the clinical presentation, course, outcome and prognostic factors of membranous lupus nephritis (MLN) in systemic lupus erythematosus (SLE) patients.</div></div><div><h3>Patients and methods</h3><div>Ninty-six SLE patients with MLN were studied. The SLE disease activity index (SLEDAI) and SLE International Collaborating Clinics damage index (SLICC-DI) were assessed. 48 patients had pure MLN (Class V) and another 48 mixed (membranous plus proliferative classes III/IV) were recruited. The median follow-up was 24 months after the initial renal biopsy.</div></div><div><h3>Results</h3><div>Out of 96 patients, 86 were females and 10 were males with a mean age of 34.9 ± 10.6 years and disease duration of 8.85 ± 1.7 years. 43 (44.8 %) had nephrotic and 25 (26 %) nephritic syndrome.The mean SLICC-DI was 2.46 ± 1.2 while SLEDAI was 12.6 ± 4.3.76 (79.2 %) achieved complete remission, and 20 (20.8 %) partial remission. 4.2 % developed renal or extra-renal flare, 13.5 % had chronic kidney disease. Patients with mixed-type had a significantly higher SLEDAI (p &lt; 0.0001), anti-double-stranded deoxyribonucleic acid (anti-dsDNA) titre (p = 0.028), serum creatinine (p = 0.016), chronicity index of renal biopsy (p = 0.001) and longer duration to achieve nephritis remission (p = 0.001) together with lower creatinine clearance (p = 0.009) in comparison with pure type. SLICC-DI &gt; 3 (p = 0.002), SLEDAI &gt; 14 (p &lt; 0.001), Albumin/ Creatinine &gt; 4.5 g/day (p = 0.013), serum creatinine &gt; 1.36 mg/dl (p &lt; 0.001), creatinine clearance &lt; 84.3 mL/min (p = 0.002), urinary casts (p &lt; 0.0001) and chronicity index &gt; 6 (p = 0.003) were the main predictors of poor outcome among patients with MLN.</div></div><div><h3>Conclusion</h3><div>Mixed MLN had more severe clinical and histological presentations and a longer time to achieve complete and partial remission than the pure MLN.</div></div>","PeriodicalId":46152,"journal":{"name":"Egyptian Rheumatologist","volume":"47 4","pages":"Pages 207-211"},"PeriodicalIF":1.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144704363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive impairment in radiographic axial spondyloarthritis patients and its relation to disease characteristics","authors":"Hania S. Zayed ,&nbsp;Radwa S. ELbahnasy ,&nbsp;Shirin M. El-Makawi ,&nbsp;Suzan S. Al-Adle","doi":"10.1016/j.ejr.2025.06.005","DOIUrl":"10.1016/j.ejr.2025.06.005","url":null,"abstract":"<div><h3>Aim of the work</h3><div>Cognitive involvement in patients with radiographic axial spondyloarthritis (r-axSpA) has not been sufficiently studied. This study aimed to assess cognitive functions in these patients and their relation to disease characteristics.</div></div><div><h3>Patients and methods</h3><div>Sixty r-axSpA patients and 60 age, sex- and education-matched healthy controls were enrolled. Disease activity was assessed by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and functional impairment by the Bath Ankylosing Spondylitis Functional Index (BASFI). Patients and controls were assessed by the Depression, Anxiety and Stress scale (DASS) and the Montreal Cognitive Assessment (MoCA) Basic test.</div></div><div><h3>Results</h3><div>The mean age of the patients was 35.8 ± 8.6 years, median disease duration of 10 years, 52 (86.7 %) were males and the educational attainment was 13.4 ± 4.7 years. The median BASDAI was 4.45 (3.75– 5.65) and BASFI was 5.1 (3.5–6.7). The patients experienced different grades of depression (78.4 %), anxiety (71.7 %) and stress (76.7 %) compared to 15 %, 31.7 %, and 30 % of the control, respectively (p &lt; 0.001). Eighteen (30 %) patients showed impaired cognitive functions on the MoCA B test (score &lt; 26) versus none of the controls (p &lt; 0.001). Executive function, immediate recall, fluency, abstraction and visuoperception were more frequently involved in patients (p = 0.001, p = 0.022, p = 0.011, p = 0.001 and p = 0.001, respectively). Impaired MoCA was significantly associated with older age (p = 0.029), lower education levels (p = 0.003), and higher BASFI (p = 0.003), but not with disease duration, BASDAI or DASS scores.</div></div><div><h3>Conclusion</h3><div>Cognitive impairment is frequent among r-axSpA patients and is associated with older age, lower educational attainment, and more functional limitations.</div></div>","PeriodicalId":46152,"journal":{"name":"Egyptian Rheumatologist","volume":"47 4","pages":"Pages 177-181"},"PeriodicalIF":1.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144513822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}